← Human Trials & Peer-Reviewed Studies
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Plain-language guide to NCT06588283: phase 3 randomized trial of Tirzepatide, psoriasis and psoriatic arthritis, 281 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06588283
- Phase
- phase 3
- Status
- completed
- Start
- 2024-09-30
- Completion (planned or actual)
- 2026-01-08
- Participants
- 281 (actual)
- Design
- randomized, open label (everyone knows who gets what), treatment
- Conditions studied
- Psoriasis; Obesity
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 3) is built around Tirzepatide for psoriasis and psoriatic arthritis.
Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
It had two arms (groups): Ixekizumab (experimental) and Ixekizumab and Tirzepatide (experimental).
Ixekizumab administered subcutaneous (SC).
Ixekizumab concomitantly administered with tirzepatide SC.
The registry classes the interventions as drug.
Who Took Part
The registry lists 281 actual participants took part.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Have a diagnosis of moderate-to-severe plaque psoriasis (PsO) for at least 6 months. Have both a Static Physician's Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) ≥12.
The full record lists 4 inclusion and 12 exclusion criteria; among the exclusions: have type 1 diabetes mellitus (t1dm); have insulin-treated type 2 diabetes mellitus (t2dm); have a prior or planned surgical treatment for obesity.
How the Study Was Run
The set-up was randomized, parallel-group and open-label.
The psoriasis and psoriatic arthritis participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.
The Tirzepatide group and the comparison group ran side by side rather than switching.
Being open-label, the Tirzepatide study did not mask who received what.
It started in 2024-09-30 with completion listed for 2026-01-08.
It ran at 72 sites in United States (68) and Puerto Rico (4).
Its stated primary purpose is treatment.
What Was Measured
It also tracked 3 secondary outcomes, for example Percentage of Participants Achieving PASI 100.
What This Means in Plain Language
Put simply, this is a phase 3, randomized trial of Tirzepatide in 281 people with psoriasis and psoriatic arthritis.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Tirzepatide compound page, Psoriasis and psoriatic arthritis research.
Our Notes on the Compound
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.